Statins and biomarkers of inflammation

Current Atherosclerosis Reports

Volumn 9, Issue 1, 2007, Pages 33-41

  Devaraj, Sridevi ^b   Rogers, Jason ^b   Jialal, Ishwarlal ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; MACROPHAGE; MONOCYTE; MONOTHERAPY; NONHUMAN; PLEIOTROPY; REVIEW; THROMBOCYTE; VASCULAR ENDOTHELIUM;

BIOLOGICAL MARKERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 33846157745     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02693938     Document Type: Review

References (71)

1. Gordon T, Kannel WB: Premature mortality from coronary heart disease: the Framingham Study. JAMA 1971, 215:1617-1625.
2. Iso H, Jacobs DR Jr, Wentworth D, et al.: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 1989, 320:904-910.
3. Pedersen TR, Kjekshus J, Berg K, et al.: Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
4. LIPID Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: the Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1988, 339:1349-1357.
5. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335:1001-1009.
6. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
7. Packard CJ: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998, 97:1440-1445.
8. Ridker PM, Rifai N, Pfefffer MA: Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
9. Kinlay S, Schwartz GG, Olsson AG, et al.: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108:1560-1566.
10. Ridker PM, Cannon CP, Morrow D, et al.: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20-28.
11. Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29-38.
12. Libby P: Inflammation in atherosclerosis. Nature 2002, 420:868-874.
13. Jialal I, Devaraj S: Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker. Am J Clin Pathol 2001, 116(Suppl):S108-115.
14. Jialal I, Devaraj S: Role of C-reactive protein in the assessment of cardiovascular risk. Am J Cardiol 2003, 91:200-202.
15. Rifai N, Ridker OM: HsCRP - a novel and promising marker of CHD. Clin Chem 2001, 47:403-411.
16. Verma S, Devaraj S, Jialal I: Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006, 113:2135-2150.
17. Ridker PM, Glynn RJ, Hennekens CH: CRP adds to the predictive value of total and HDL cholesterol in determining risk of first MI. Circulation 1998, 97:2007-2011.
18. Ridker PM, Hennekens CH, Buring JE, et al.: CRP and other markers of inflammation in the prediction of CAD in women. N Engl J Med 2000, 342:836-843.
19. Ridker PM, Cushman M, Stampfer MJ, et al.: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97-425-428.
20. Cushman M, Arnold AM, Psaty BM, et al.: C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study. Circulation 2005, 112:25-31.
21. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for health-care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511.
22. Ridker PM, Rifai N, Pfeffer MA, et al.: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999, 100:230-235.
23. Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
24. Jialal I, Stein D, Balis D, et al.: Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933-1935.
25. Miller M, Jialal I: Effects of simvastatin (40 and 80 mg) on highly sensitive C-reactive protein in patients with combined hyperlipidemia. Am J Cardiol 2001, 89:468-469.
26. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001, 103:1191-1193.
27. Albert MA, Danielson E, Rifai N, et al.: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
28. Tan KC, Chow WS, Tam SC, et al.: Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab 2002, 87:563-568.
29. Van de Ree MS, Huisman MV, Princen HM, et al.: Strong decrease of hsCRP with high dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003, 166:129-135.
30. Horne BD, Muhlestein JB, Carlquist JF, et al.: Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe CAD. J Am Coll Cardiol 2000, 36:1774-1780.
31. Reisen WF, Engler H, Risch M, et al.: Short term effects of atorvastatin on CRP. Eur Heart J 2002, 23:794-799.
32. van Wissen S, Trip MD, Smilde TJ, et al.: Differential hsCRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002, 165:361-366.
33. Taylor AJ, Kent SM, Flaherty PJ, et al.: ARBITER:Arterial biology for the investigation of treatment effects of reducing cholesterol. Circulation 2002, 106:2055-2060.
34. Cortellaro M, Cofrancesco E, Boschetti C, et al.: Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, tPA and CRP in CAD patients with mixed hyperlipidemia(FACT Study). Thromb Hemost 2000, 83:549-553.
35. de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316.
36. Morrow DA, deLemos JA, Sabatine MS, et al.: Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation 2006 114:281-288.
37. Wilson SH, Simari RD, Best PJ, et al.: Simvastatin preserves coronary endothelial function in hypercholesterolemia in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 2001, 21:122-128.
38. Sukhova GK, Williams JK, Libby P: Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 2002, 22:1452-1458.
39. Dupuis J, Tardif JC, Cernacek P, ct al.: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999, 99:3227-3233.
40. Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
41. Kinlay S, Libby P, Ganz P: Endothelial function and coronary artery disease. Curr Opin Lipidol 2001, 12:383-389.
42. Egashira K, Hirooka Y, Kai H, et al.: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994, 89:2519-2524.
43. Treasure CB, Klein JL, Weintraub WS, et al.: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995, 332:481-487.
44. Fabian E, Varga A: Effect of simvastatin therapy on endothelial function of hypercholesteremic patients with syndrome X. Orv Hetil 2002, 143:2067-2071.
45. Liao JK: Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002, 86:5-18.
46. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme: a reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
47. Koh KK: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657.
48. Niwa S, Totsuka T, Hayashi S: Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996, 18:669-675.
49. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7:687-692.
50. Serrano CV, Yoshida VM, Venturinelli ML, et al.: Effect of simvastatin on monocytes adhesion molecule expression in patients with hypercholesterolemia. Atherosclerosis 2001, 157:505-512.
51. Weber C, Erl W, Weber PC: HMGCoA reductase inhibitors decrease CD11b expression and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997, 30:1212-1217.
52. Ferro D, Parrotto S, Basili S, et al.: Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol 2000, 36:427-431.
53. Bustos C, Hernandez-Presa MA, Ortego M, et al.: HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998, 32:2057-2064.
54. Rezai Majd A, Maca T, Bucek RA, et al.: Simvastatin reduces expression of cytokines IL-6,IL-8 and MCP-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002, 22:1194-1199.
55. Colli S, Eligini S, Lalli M, et al.: Vastatins inhibit tissue factor in cultured human macrophages: a novel mechanism of protection against atherothrombosis. Arterioscler Thromb Vasc Biol 1997, 17:265-272.
56. Devaraj S, Chan E, Jialal I: Direct demonstration of the antiinflammtory effects of simvastatin in patients with metabolic syndrome. J Clin Endocrinol Metab 2006, In press.
57. Mohiuddin I, Chai H, Lin PH, et al.: Nitrotyrosine and chlorotyrosine: clinical significance and biological functions in the vascular system. J Surg Res 2006, 133:143-149.
58. Shishehbor MH, Aviles RJ, Brennan ML, et al.: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA 2003, 289:1675-1680.
59. Nicholls SJ, Hazen SL: Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol 2005, 25:1102-1111.
60. Shishehbor MH, Brennan ML, Aviles RJ, et al.: Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003, 108:426-431.
61. Caslake MJ, Packard CJ: Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke. Nat Clin Pract Cardiovasc Med 2005, 2:529-535.
62. O'Donoghue M, Morrow DA, Sabatine MS, et al.: Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 2006, 113:1745-1752.
63. Rasmussen LM, Hansen PR, Nabipour MT, et al.: Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells. Biochem J 2001, 360(Pt 2):363-370.
64. Yoshida M, Sawada T, Ishii H, et al.: HMG-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001, 21:1165-1171.
65. Laufs U, La Fata V, Plutzky J, et al.: Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998, 97:1129-1135.
66. Dichtl W, Dulak J, Frick M, et al.: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003, 23:58-63.
67. Li AC, Binder CJ, Gutierrez A, et al.: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004, 114:1564-1576.
68. Zelvyte I, Dominaitiene R, Crisby M, et al.: Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002, 45:147-154.
69. Landrier JF, Thomas C, Grober J, et al.: Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent. J Biol Chem 2004, 279:45512-45518.
70. Inoue I, Itoh F, Aoyagi S, et al.: Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002, 290:131-139.
71. Ridker PM: JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292-2297.